Form 8-K - Current report:
SEC Accession No. 0001104659-25-021379
Filing Date
2025-03-06
Accepted
2025-03-06 16:17:17
Documents
15
Period of Report
2025-03-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm258283d1_8k.htm   iXBRL 8-K 26936
2 EXHIBIT 99.1 tm258283d1_ex99-1.htm EX-99.1 92369
6 GRAPHIC image_001.jpg GRAPHIC 4057
  Complete submission text file 0001104659-25-021379.txt   311731

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20250306.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20250306_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20250306_pre.xml EX-101.PRE 22378
17 EXTRACTED XBRL INSTANCE DOCUMENT tm258283d1_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 25715484
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)